Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2024-06-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
第五届董事会第二次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the company's fifth board of directors' second (extraordinary) meeting. It details the approval of a related-party transaction involving the transfer of a wholly-owned subsidiary's equity. The document includes voting results and references to related documents but does not contain financial statements or detailed financial analysis. It is a formal disclosure of board decisions, specifically about management-level decisions and corporate governance matters. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on board resolutions, not a full report or financial filing.
2024-06-28 Chinese
关于转让全资子公司股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the transfer of 100% equity of a wholly-owned subsidiary, Wuhan Lvkang Biochemical Technology Co., Ltd., to a related party, Fujian Putan Thermal Energy Co., Ltd. It details the transaction price, the decision-making process, related party relationships, financial data of the involved parties, pricing policy, and the impact on the company. The document is structured as a formal announcement of a related party transaction and equity transfer, including board approvals and independent director opinions. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, earnings release, or other report types. The content fits best with a Capital/Financing Update (CAP) as it concerns a significant change in the company's capital structure through the sale of a subsidiary's equity and related party transaction disclosures. The document length is 4458 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2024-06-28 Chinese
关于公司与硕腾比利时公司签订供应协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a supply agreement between the company (绿康生化股份有限公司) and Zoetis Belgium S.A. It details the terms of the supply agreement, the parties involved, and the expected impact on the company. There is no financial report, earnings data, or detailed financial analysis included. The document is a formal announcement of a business agreement, which relates to ongoing operations and supply contracts, not a financial report or regulatory filing about financial results or governance changes. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a capital or financing update, nor a legal proceeding or merger announcement. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-06-28 Chinese
关于选举董事长、董事会专门委员会委员、监事会主席暨聘任高级管理人员及证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is an official announcement from a company regarding the election of the chairman, members of the board's specialized committees, the chairman of the supervisory board, and the appointment of senior management and securities affairs representatives. It includes detailed information about the individuals elected or appointed, their qualifications, and their shareholdings. The document is dated around the time of the company's annual general meeting (AGM) and relates to governance and management changes following that meeting. There is no financial data or report content, but rather an announcement of changes in the company's board and senior management. Therefore, this document fits the category of Board/Management Information (MANG). The document length (7091 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive announcement of management changes.
2024-05-21 Chinese
第五届董事会第一次（临时）会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the first (extraordinary) meeting of the fifth board of directors of the company. It details the election of the chairman, appointment of board committees, senior management appointments, and approval of a loan collateral arrangement. The document includes voting results and references to further announcements on other platforms. It does not contain financial statements or detailed financial performance data. The content is focused on board and management changes and decisions. The document length is under 5,000 characters and is an announcement of board decisions rather than a full report. Therefore, it fits the category of Board/Management Information (MANG).
2024-05-21 Chinese
关于公司向银行贷款补充抵押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company 绿康生化股份有限公司 regarding the company's decision to provide additional collateral (mortgage) for a bank loan. It details board meeting resolutions approving the use of company-owned real estate as supplementary collateral for an 85 million RMB loan. The document includes assurances about the legitimacy and impact of the transaction, and states that it is not a related party transaction or a major asset restructuring. The document is short (1003 characters) and is an announcement of a financing-related event, specifically about loan collateral. It does not contain financial statements or detailed financial data, nor is it a full report or audit. It fits best under Capital/Financing Update (CAP) as it relates to financing activities and capital structure changes.
2024-05-21 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.